Skip to main content
. 2021 Mar 19;20:54. doi: 10.1186/s12943-021-01338-2

Table 1.

RNA based therapeutics in clinical trials in lung cancer

Drug combination Affected Pathway References
Custirsen + gemcitabine + cisplatin Clusterin [288]
Aprinocarsen + gemcitabine + cisplatin PKC-a [300, 303, 304]
Imetelstat + bevacizumab Telomerase [286]
LY2181308 + docetaxel Survivin [305]
Oblimersen + paclitaxel Bcl2 [283]
Oblimersen + carboplatin + etoposide Bcl2 [285]